Editing Formoterol (section)

==Side effects==
In November 2005, the US [[Food and Drug Administration]] (FDA) released a health advisory alerting the public to findings that show the use of long-acting β<sub>2</sub> agonists could lead to a worsening of wheezing symptoms in some patients.<ref>{{cite web | work=U.S. [[Food and Drug Administration]] (FDA) | title=Advair Diskus, Advair HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and Symbicort Information (Long Acting Beta Agonists) | url=https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm | access-date=16 December 2019 | archive-date=1 November 2017 | archive-url=https://web.archive.org/web/20171101115959/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm | url-status=dead }}</ref>

Nowadays, available long-acting β<sub>2</sub> agonists include [[salmeterol]], formoterol, [[bambuterol]], and sustained-release oral [[salbutamol]].

Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread – combination preparations include [[fluticasone/salmeterol]] and [[budesonide/formoterol]].